Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab (2016) Bumes E, Rzonsa S, Hutterer M, Proescholdt M, Bogdahn U, Riemenschneider MJ, Uhl M, et al. Journal article Recurrent glioblastoma: who receives tumor specific treatment and how often? (2016) Steffens R, Semrau S, Lahmer G, Putz F, Lettmaier S, Eyüpoglu IY, Buchfelder M, Fietkau R Journal article Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma (2014) Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F, Bendszus M, et al. Journal article Papillary tumor of the pineal region with anaplastic small cell component (2013) Heim S, Coras R, Ganslandt O, Kufeld M, Blümcke I, Paulus W, Hasselblatt M Journal article Re-irradiation in recurrent malignant glioma: Prognostic value of [ 18F]FET-PET (2012) Niyazi M, Jansen N, Ganswindt U, Schwarz SB, Geisler J, Schnell O, Büsing K, et al. Journal article Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. (2006) Wegner M, Stolt C Journal article, Original article